Statistics for Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
Total visits
| views | |
|---|---|
| Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study | 103 |
Total visits per month
| views | |
|---|---|
| June 2025 | 4 |
| July 2025 | 1 |
| August 2025 | 4 |
| September 2025 | 5 |
| October 2025 | 0 |
| November 2025 | 0 |
| December 2025 | 0 |
File Visits
| views | |
|---|---|
| Long_safety.pdf | 2 |
Top country views
| views | |
|---|---|
| United States | 28 |
| Portugal | 9 |
| China | 8 |
| United Kingdom | 7 |
| Canada | 6 |
| Germany | 6 |
| Australia | 4 |
| Brazil | 4 |
| Ireland | 4 |
| France | 3 |
| Turkey | 3 |
| Russia | 2 |
| Bangladesh | 1 |
| Switzerland | 1 |
| Colombia | 1 |
| Ecuador | 1 |
| Egypt | 1 |
| India | 1 |
| Iran | 1 |
| Japan | 1 |
| Kenya | 1 |
| Netherlands | 1 |
| New Zealand | 1 |
| Paraguay | 1 |
| Tunisia | 1 |
| Uzbekistan | 1 |
| Vietnam | 1 |